argenx SE (ARGX)
NASDAQ: ARGX
· Real-Time Price · USD
637.09
-8.05 (-1.25%)
At close: May 01, 2025, 12:06 PM
-1.25% (1D)
| Bid | 637 |
| Market Cap | 38.9B |
| Revenue (ttm) | 2.15B |
| Net Income (ttm) | 805.17M |
| EPS (ttm) | 12.77 |
| PE Ratio (ttm) | 49.89 |
| Forward PE | 30.92 |
| Analyst | Buy |
| Ask | 816.93 |
| Volume | 61,040 |
| Avg. Volume (20D) | 344,003 |
| Open | 643.33 |
| Previous Close | 645.14 |
| Day's Range | 631.52 - 645.60 |
| 52-Week Range | 352.77 - 678.21 |
| Beta | 0.20 |
About ARGX
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemp...
Industry Biotechnology
Sector Healthcare
IPO Date May 18, 2017
Employees 1,599
Stock Exchange NASDAQ
Ticker Symbol ARGX
Website https://www.argenx.com
Analyst Forecast
According to 21 analyst ratings, the average rating for ARGX stock is "Buy." The 12-month stock price forecast is $704, which is an increase of 10.50% from the latest price.
Stock ForecastsNext Earnings Release
argenx SE is scheduled to release its earnings on May 8, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
+3.01%
Argenx shares are trading higher after the company...
Unlock content with
Pro Subscription
5 months ago
+2.34%
Argenx shares are trading higher after Scotiabank upgraded the stock from Sector Perform to Sector Outperform and raised its price target from $439 to $715.
